{"entity":{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","aka":["Abbisko Therapeutics Co, Ltd","和誉生物"],"tldr":"Abbisko is a Shanghai biotech listed in Hong Kong whose CSF-1R inhibitor pimicotinib was approved in China in December 2025 for tenosynovial giant cell tumour, a rare joint tumour, and is licensed worldwide to Merck KGaA.","summary":"Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour; Merck KGaA exercised its global commercialisation option in April 2025 for a USD 85 million fee. China's regulator approved pimicotinib in December 2025 for adults with symptomatic tenosynovial giant cell tumour where surgery would cause functional limitation or severe morbidity, and the FDA accepted a new drug application in January 2026. FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.abbisko.com"},{"label":"HKEX: pimicotinib approved by China NMPA (22 December 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1222/2025122200538.pdf"},{"label":"HKEX: Merck exercises global option for pimicotinib (1 April 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0401/2025040100115.pdf"},{"label":"HKEX: FDA accepts pimicotinib application (13 January 2026)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0113/2026011300141.pdf"},{"label":"ClinicalTrials.gov: trials led by Abbisko Therapeutics Co, Ltd","url":"https://clinicaltrials.gov/search?lead=Abbisko%20Therapeutics%20Co%2C%20Ltd"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045781"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tenosynovial-giant-cell-tumour","hcc"],"sections":[],"technologies":[],"targets":["csf1r"],"drugs":["absk061","pimicotinib"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06632262","nct07164170","nct06668103","nct05804045","nct07327034","nct06111274","nct07417189"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026 from HKEX announcements for stock code 2256. No FDA decision on pimicotinib had been announced by 29 October 2026. Shareholders approved on 17 September 2026 renaming the listed parent from Abbisko Cayman Limited to Abbisko Medicine Co., Ltd., effective once the Cayman Islands registrar issues the certificate; whether that has happened was not confirmed. The operating subsidiary remains Abbisko Therapeutics Co., Ltd."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.abbisko.com","ticker":"2256.HK","stage":"public","investors":[],"funding":[]},"route":"/companies/abbisko/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/"}],"target":[{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/"}],"drug":[{"id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/"},{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/"}],"company":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/"},{"id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/"},{"id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/"},{"id":"nct06111274","kind":"trial","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06111274/"},{"id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","route":"/trials/nct07710612/"},{"id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/"},{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/"},{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","route":"/trials/nct05804045/"}]}}